Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study

Cancer

Volumn 118, Issue 1, 2012, Pages 63-71

  Araujo, John C ^a   Mathew, Paul ^b   Armstrong, Andrew J ^c   Braud, Edward L ^d   Posadas, Edwin ^e   Lonberg, Mathew ^f   Gallick, Gary E ^a   Trudel, Géralyn C ^g   Paliwal, Prashni ^g   Agrawal, Shruti ^g   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d Springfield Clinic   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Hematology Oncology Associates of Rockland   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

bone; dasatinib; docetaxel; metastases; prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DASATINIB; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; FATIGUE; HUMAN; HYPOKALEMIA; INSOMNIA; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; SENSORY NEUROPATHY; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CASTRATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIMIDINES; TAXOIDS; THIAZOLES;

EID: 83855162892     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26204     Document Type: Article

References (34)

1. Soloway MS, Ishikawa S, van der Zwaag R, Todd B,. Prognostic factors in patients with advanced prostate cancer. Urology. 1989; 33: 53-56. (Pubitemid 19123267)
2. Ernst DS, Hanson J, Venner PM,. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol. 1991; 146: 372-376.
3. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 948-957. (Pubitemid 29109328)
4. Noguchi M, Kikuchi H, Ishibashi M, Noda S,. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003; 88: 195-201. (Pubitemid 36255835)
5. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001; 357: 336-341. (Pubitemid 32128538)
6. Chen N, Ye XC, Chu K, et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007; 67: 6544-6548. (Pubitemid 47105497)
7. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1: 944-949.
8. Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res. 2010; 16: 121-129.
9. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer. 2003; 39: 1927-1935. (Pubitemid 37311191)
10. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005; 65: 9185-9189. (Pubitemid 41507982)
11. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68: 3323-3333.
12. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E,. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009; 101: 263-268.
13. Goldenberg-Furmanov M, Stein I, Pikarsky E, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 2004; 64: 1058-1066. (Pubitemid 38176910)
14. Posadas EM, Al-Ahmadie H, Robinson VL, et al. FYN is overexpressed in human prostate cancer. BJU Int. 2009; 103: 171-177.
15. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J,. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009; 15: 3540-3549.
16. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R,. Src kinase activity is essential for osteoclast function. J Biol Chem. 2004; 279: 17660-17666. (Pubitemid 38560531)
17. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR,. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992; 90: 1622-1627.
18. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003; 63: 5028-5033. (Pubitemid 37022641)
19. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006; 318: 161-172.
20. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009; 16: 67-78.
21. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658-6661. (Pubitemid 40053752)
22. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007; 67: 2226-2238. (Pubitemid 46424242)
23. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007; 25: 1035-1044. (Pubitemid 47517638)
24. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467. (Pubitemid 29517916)
25. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
26. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204-3212.
27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520. (Pubitemid 39315318)
28. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
29. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009; 15: 7421-7428.
30. Yu EY, Massard C, Gross M, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085) [abstract]. J Clin Oncol. 2009; 27 (suppl 15): 270s. Abstract 5147.
31. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008; 112: 326-330.
32. Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008; 14: 6270-6276.
33. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007; 13: 5816-5824. (Pubitemid 47583906)
34. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879-882. (Pubitemid 38807610)